www.xinhuanet.com
XINHUA online
CHINA VIEW
VIEW CHINA
 Breaking News Strong earthquake jolts NE Afghanistan     Urgent: Pro-Syrian ministers suspend participation in Lebanese gov't    Urgent: UN inquiry says Syria failed to fully cooperate with investigation    NATO discovers weapon cache in Kabul    3 killed in armed raid in SE. Turkey    Strong blast rocks central Athens    
Home  
China  
World  
Business  
Technology  
Opinion  
Culture/Edu  
Sports  
Entertainment  
Life/Health  
Travel  
Weather  
RSS  
  About China
  Map
  History
  Constitution
  CPC & Other Parties
  State Organs
  Local Leadership
  White Papers
  Statistics
  Major Projects
  English Websites
  BizChina
- Conferences & Exhibitions
- Investment
- Bidding
- Enterprises
- Policy update
- Technological & Economic Development Zones
Online marketplace of Manufacturers & Wholesalers
   News Photos Voice People BizChina Feature About us   
China granted license to produce Tamiflu
www.chinaview.cn 2005-12-12 20:37:57

    SHANGHAI, Dec. 12 (Xinhuanet) -- Shanghai Pharmaceutical Group announced here Monday it has reached a sublicensing deal with the Swiss Roche for the production of Tamiflu, a drug widely believed to be effective in treating human cases of bird flu, in China.

    Roche also made an announcement at its website Monday, saying "Roche and Shanghai Pharmaceutical Group have signed the first sub-licensing agreement for the overall production of oseltamivir for pandemic use in China."

    The brand name of oseltamivir is Tamiflu. Jointly developed by Gilead and Roche, the drug has been recommended by the World Health Organization in treating human cases of the bird flu.

    Roche has exclusive world-wide rights for the manufacturing and marketing of Tamiflu and continues to work in partnership with Gilead, according to Roche.

    The announcement said Roche is also "in negotiations for local partnerships in other countries."

    An official with the Shanghai Pharmaceutical Group said its products will not bear the name of "Tamiflu", but the ingredients and quality will be the same with Tamiflu produced by Roche.

    He said the group aims to form a monthly production capacity of200,000 treatments in six months in the first step.

    According to the official, the group made the request to produce and sell Tamiflu under a sub-license in November. Enditem

  Related Story
Copyright ©2003 Xinhua News Agency. All rights reserved.
Reproduction in whole or in part without permission is prohibited.